Are patients ‘promiscuous’, or simply adapting?

Good morning. It is Wednesday 10 June 2026, and this issue runs about 750 words, a 5-minute read. This issue: a word used about patients at an industry event, why most of your medicine is called ‘unlicensed’ and what that does and does not mean, a milestone for a cannabis pain drug, and a scary driving headline worth a calm second look. We end somewhere hopeful.

At an industry discussion about why medical cannabis supply keeps wobbling, someone reached for a striking phrase: ‘patient promiscuity’. The idea is that patients switch products too often, which pushes growers toward novelty instead of steady, reliable supply. The label puts the blame in the wrong place.

What this means for you: if you have changed product or clinic, that is not fickleness. It is a sensible response to a young market with patchy supply, high costs, and little clinical guidance. When the product that works for you goes out of stock, or a cheaper equivalent appears, switching is what a careful patient does.

The other side, fairly: the supply worry is real. Growers and clinics cannot plan production if demand jumps between products, and unstable supply hurts patients too, so the industry’s underlying problem is genuine, even if ‘promiscuity’ is the wrong word for it.

Where we land: the label blames patients for a system patients did not design. The fix sits with the industry: clearer supply commitments, better guidance, and honesty about which products will still exist in six months. That would serve patients, so we are for it.

More on what shapes the price and supply of your medicine: What it costs.

Source: an industry panel discussion, June 2026. We have reported the debate, not adopted a side

Plain English: ‘unlicensed medicine’

The term. Most medical cannabis prescribed privately in the UK, the flower and many oils, is an ‘unlicensed medicine’. That sounds alarming. It is more ordinary than it sounds.

What it means. A licensed medicine has been formally approved by the UK regulator, the MHRA, as safe and effective for a specific use, and carries what is called a marketing authorisation. An unlicensed medicine has not been through that approval for this use. Only a few cannabis medicines are licensed in the UK. The rest are prescribed ‘unlicensed’, on the judgement and responsibility of a specialist who decides it suits you when no licensed option does.

Why it matters to you. It is the reason only a specialist, not your GP, can start your treatment, and the reason they take extra care. It does not mean the medicine is illegal, untested, or unsafe. It means the formal licence for this particular use is not in place. It is also why the pain-drug news below, a cannabis medicine seeking a licence, is a notable step.

Glossary · unlicensed medicine: a medicine not formally licensed by the MHRA for the use it is prescribed for. Legal, and prescribable by a specialist on their judgement. One term decoded each week.

For the official picture, see the NHS page on medical cannabis and NICE guideline NG144. Not medical advice.

Also this week

▸ A non-opioid cannabis pain drug clears a US hurdle. The US regulator gave ‘Breakthrough Therapy’ status to VER-01, a cannabis-based drug for chronic low back pain from the German firm Vertanical, a step that speeds up review. In two trials, the company reported it reduced pain with no sign of dependence.

Why this matters: if it is eventually approved, it would be among the first licensed cannabis medicines for pain, a sign the science is being taken seriously. The caveats are large. This is a US milestone, not approval. Full approval is years away, 2028 at the earliest. The trials were funded by the maker, and the results apply only to that specific product, not to cannabis in general or to what you are prescribed today.

Source: Vertanical company announcement, and the US FDA

▸ Seen the scary DVLA driving headline? A headline about prescription medicines that ‘trigger automatic driving bans’ did the rounds again. The calm reality: if your cannabis is prescribed and you are not impaired, a medical defence protects you, even though THC has a legal limit. The ‘automatic ban’ framing leaves that defence out.

UK drug-driving law ↗

Source: UK drug-driving law. Not legal advice.

One good thing

Australia’s most populous state, New South Wales, is ending automatic licence loss for medical cannabis patients who drive responsibly, moving to a registration-and-threshold scheme rather than punishing any trace of THC. It is a reminder that the law is slowly catching up with patients. And worth knowing: on this point, UK patients are already ahead, since our medical defence for prescribed, unimpaired driving exists today.

Source: the NSW Government, announced 4 June 2026.